As a leading research-driven pharmaceutical company, Getz Pharma continuously supports scientific initiatives to help address healthcare challenges. Taking a step forward in this direction, Getz Pharma conducted the SAFE-PAK study, Pakistan’s first randomized controlled clinical trial to test the safety and efficacy of Empagliflozin – a medicine used to treat type 2 diabetes. Getz Pharma unveiled the promising results of the SAFE-PAK study with the leading health care fraternity at the 7th Mid-Summer Endocrine Updates, hosted by the Pakistan Endocrine Society.
Diabetes is one of the fasting-growing diseases in the world. According to a recent survey, around 16.98% of the Pakistani population is diabetic. The high usage of junk food paired with an unhealthy lifestyle and no physical activity are the common factors leading to type 2 diabetes. Understanding the need to combat this disease, pharmaceutical scientists have developed Empagliflozin, after conducting extensive clinical trials.
Elaborating further on this, Professor. Dr. A.H. Aamir, Endocrinologist and Principal Investigator of Getz Pharma’s SAFE-PAK study, shared with the healthcare fraternity that extensive research has been carried out to test the safety and efficacy of Empagliflozin in the local Pakistani-Muslim population. Previously, research has been conducted on Empagliflozin in western countries, but this is the first time a randomized controlled trial has been carried out on Empagliflozin, keeping in mind the environmental conditions and hygiene practices of the local Pakistani-Muslim population. The study showed that this molecule is, in fact, a safe drug of choice among the targeted population.
Furthermore, Dr. Aamir shared that the success and credibility of this study have been recognized by international societies, and poster/oral presentations have been shared at international forums such as the Diabetes UK conference and the annual meeting of the American Association of Clinical Endocrinology.
With the help of the SAFE-PAK study, Getz Pharma hopes to provide medical professionals a comprehensive research framework to treat patients with type 2 diabetes, effectively addressing the safety concerns.
You are about to be redirected to an online retailer’s website. Getz Pharma is not liable for any data exchange on the new website
You will be redirected in 3secs
Disclaimer: "This message (including attachment) is intended solely for the use of the individual or entity whom it is addressed and may contain information that is confidential or privileged. If you are not the intended recipient of this message, you are hereby notified that any use, dissemination, distribution or reproduction of this message is prohibited and that, you must not take any action in reliance on it. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrived incomplete or contain viruses; therefore Getz Pharma (Private) Limited cannot accept legal responsibility for the contents of this message. If you have received this communication in error, please notify the sender or Getz Pharma (Private) Limited at [email protected] immediately and destroy the original message."
Close
